Lupus Nephritis Ln clinical trials

Explore recruiting lupus nephritis ln clinical trials.

Recruiting lupus nephritis ln studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lupus Nephritis Ln trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 To < 12)

Spain, France, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis

Spain, Italy, Germany, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Italy, Poland, Spain, Sweden, France, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double‑blind, Placebo‑controlled, Dose‑finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Germany, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, open-label study to evaluate the efficacy and safety of rapcabtagene autoleucel in patients with active, refractory systemic lupus erythematosus (SLE), or active, refractory lupus nephritis (LN).

France, Spain, Italy, Netherlands, Germany, Czechia +7 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

France, Spain, Portugal, Germany, Belgium, Poland +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Lupus Nephritis Ln trials by city

Lupus Nephritis Ln in Toronto Lupus Nephritis Ln in Vancouver Lupus Nephritis Ln in Montreal Lupus Nephritis Ln in Calgary Lupus Nephritis Ln in Edmonton Lupus Nephritis Ln in Ottawa Lupus Nephritis Ln in Winnipeg Lupus Nephritis Ln in Quebec City Lupus Nephritis Ln in Hamilton Lupus Nephritis Ln in Kitchener Lupus Nephritis Ln in London Lupus Nephritis Ln in Halifax Lupus Nephritis Ln in New York Lupus Nephritis Ln in Los Angeles Lupus Nephritis Ln in Chicago Lupus Nephritis Ln in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease